NG Biotech
Rapid in vitro diagnostic tests for healthcare professionals, patients and global partners
Highlights
- Hiring2 open roles
- New on EvolcAdded 2026-10-29
About NG Biotech
NG Biotech develops, manufactures and markets rapid in vitro diagnostic tests for screening, diagnosis, monitoring and prevention. Its patented immunoassay platform supports qualitative and multiplex point-of-care tests using blood or other samples.
The company sells CE-marked tests worldwide and also develops and manufactures diagnostic solutions for partners. Its product areas include antimicrobial resistance, infectious diseases, women’s health, self-tests and veterinary diagnostics.
Founded in 2012, NG Biotech is based in Guipry-Messac, France, where it operates an industrial site integrating product design, development and manufacturing. The company is ISO 13485:2016 and MDSAP certified, and is hiring for international sales and export administration roles.
Product: Rapid in vitro diagnostic tests and partner-focused development and manufacturing of diagnostic solutions.
Jobs at NG Biotech (2)
NG Biotech is hiring for 2 roles in customer support and sales, based in Guipry-Messac.
Companies hiring like NG Biotech
Leadership
- Alain Calvo · Co-Founder & General AdvisorSource: company website
- Milovan Stankov · Co-Founder & General AdvisorSource: company website
- Milovan Stankov Pugès · President & CEOSource: company website
More biotech & pharma companies
Noraker
Develops and manufactures resorbable biomaterial implants for surgeons treating bone defects and supporting bone regenerationNew on EvolcNovalix
Preclinical drug discovery services for biotechnology and pharmaceutical companiesNew on EvolcNovaptech
Custom aptamer development, assays and biosensors for biotechnology, pharmaceutical, academic and agri-food organizationsNew on EvolcOddifact
AI platform that prepares orphan drug programs for rare diseases and hands them to pharma partners for developmentYoung companyNew on EvolcOGD2 Pharma
Biotherapy developer targeting the tumour-restricted OAcGD2 antigen for high-risk neuroblastoma treatmentNew on EvolcOncodesign Services
Preclinical CRO running in vivo pharmacology, imaging and radiopharmaceutical studies for biotech and pharma sponsorsNew on EvolcRemote-friendly
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Cookiebot
- Google Analytics 4
- WordPress
- jQuery